HMH Hospitals Corp DBA CDI
The Center for Discovery and Innovation (CDI) is a research institute focused on biomedical sciences, with a mission to harness innovations in biomedical sciences to restore patient health. It conducts research across various focus areas including behavioral and neurocognitive health, cancer, immunology, infectious diseases, and more. CDI offers advanced research facilities, supports translational research, and fosters collaborations to develop new diagnostics, therapies, and understanding of human diseases. The institute is actively recruiting faculty and provides training programs for researchers and clinicians.
Industries
Nr. of Employees
medium (51-250)
HMH Hospitals Corp DBA CDI
Center for Discovery and Innovation, 111 Ideation Way, Nutley, NJ 07110
Patents
Pumpless platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation
US-11421194-B2
View Details
Pumpless platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation
US-11421194-B2
View DetailsProducts
ETMR One registry (international rare tumor data platform)
International registry and research platform for embryonal tumor with multilayer rosettes (ETMR) that centralizes clinical data, enables consensus therapy review, and supports collaborative rare-disease research.
ETMR One registry (international rare tumor data platform)
International registry and research platform for embryonal tumor with multilayer rosettes (ETMR) that centralizes clinical data, enables consensus therapy review, and supports collaborative rare-disease research.
Services
Immunophenotyping, immunological function assays, assay development, sample preparation (stimulation and staining), instrumentation training, and consultation for translational immunology research.
Partnerships and core services for genomics, epigenomics, sequencing, and bioinformatics to support variant discovery, methylation profiling, and downstream analysis.
MSI-based spatial pharmacokinetics and spatial pharmacodynamics analyses, biomarker identification, and method development for translational pharmacology studies.
Design and execution support for animal experiments including genetically engineered models, infection models, and large-animal testing for tissue-engineered grafts.
Development, validation, and evaluation of molecular diagnostic assays (multiplex PCR and related methods) and assessment of rapid molecular diagnostics to inform therapy.
Immunophenotyping, immunological function assays, assay development, sample preparation (stimulation and staining), instrumentation training, and consultation for translational immunology research.
Partnerships and core services for genomics, epigenomics, sequencing, and bioinformatics to support variant discovery, methylation profiling, and downstream analysis.
MSI-based spatial pharmacokinetics and spatial pharmacodynamics analyses, biomarker identification, and method development for translational pharmacology studies.
Design and execution support for animal experiments including genetically engineered models, infection models, and large-animal testing for tissue-engineered grafts.
Development, validation, and evaluation of molecular diagnostic assays (multiplex PCR and related methods) and assessment of rapid molecular diagnostics to inform therapy.
Expertise Areas
- Genomics and epigenomics
- Cancer biology and tumor microenvironment
- Immunology and cellular immunotherapy
- Infectious disease research and antimicrobial resistance
Key Technologies
- Array-based CpG methylation profiling
- Methylation sequencing (Methyl-Seq)
- Allele-specific methylation mapping
- CRISPR/Cas9 gene editing
News & Updates
Research published by a CDI lab shows promise in developing an exhaled-breath test for lung diseases including lung cancer.
Research published by a CDI lab shows promise in developing an exhaled-breath test for lung diseases including lung cancer.